Bristol Myers Squibb (BMY) Equity Income (2009 - 2024)

Bristol Myers Squibb has disclosed Equity Income across 15 years of filings, most recently posting -$23.0 million for Q3 2024.

• In Q3 2024, Equity Income fell 227.78% year-over-year to -$23.0 million; the TTM figure through Sep 2024 stood at $12.0 million (down 84.42% YoY), while the FY2019 annual figure was -$4.0 million, down 104.3% from the prior year.
• Equity Income eased to -$23.0 million in Q3 2024, from $28.0 million in the prior quarter.
• Over the last five years, Equity Income for BMY reached as high as $40.0 million in Q3 2021 and fell as low as -$23.0 million in Q3 2024.
• The 4-year median for Equity Income is $23.0 million (2023), against an average of $13.7 million.
• The widest YoY moves for Equity Income: up 354.55% in 2024, down 227.78% in 2024.
• A 4-year view of Equity Income shows it stood at $30.0 million in 2020, then soared by 33.33% to $40.0 million in 2021, then slumped by 55.0% to $18.0 million in 2023, then slumped by 227.78% to -$23.0 million in 2024.
• According to Business Quant data, Equity Income over the past three periods registered -$23.0 million, $28.0 million, and $18.0 million for Q3 2024, Q2 2024, and Q3 2023 respectively.